Pharming Group N.V. to Attend Rare Disease Summit
Pharming Group N.V. (NASDAQ: PHAR), a pioneering biopharmaceutical company, has recently confirmed its participation in the exclusive Oppenheimer Movers in Rare Disease Summit. This significant event is designed for innovative companies and investors who are keenly focused on the unique challenges posed by rare diseases.
Fireside Chat Highlight
At the summit, attendees will have the opportunity to hear from Anurag Relan, M.D., the Chief Medical Officer of Pharming. He will engage in a fireside chat that delves into the hereditary angioedema (HAE) market. This discussion is scheduled for 1:50 PM ET / 19:50 CET and promises to offer insights into recent advancements and future prospects in HAE treatment.
One-on-One Meetings With Management
Pharming encourages investors and interested parties to take part in meaningful discussions surrounding their innovative strategies and upcoming projects. Those wishing to arrange one-on-one meetings with Pharming's management can reach out to Investor Relations through their official contact channels. This provides a fantastic chance for stakeholders to engage directly with the leadership team.
Overview of Pharming Group N.V.
Pharming Group N.V. is at the forefront of developing innovative therapies aimed to change the lives of patients affected by rare and severe conditions. With a diverse portfolio, Pharming is dedicated to offering both small molecules and biologics that can make a significant impact in the biopharmaceutical landscape.
Innovative Medicines and Patient Commitment
The company’s operations are deeply rooted in patient-centric care. By addressing complex and life-threatening conditions, Pharming continues to push boundaries in drug development, underlining its commitment to improving patient outcomes globally. The company is headquartered in Leiden, the Netherlands, with a substantial portion of its workforce in the U.S., demonstrating its international reach and dedication to healthcare.
Company Contact Information
For further inquiries or to learn more about Pharming’s initiatives, contact Investor Relations. Michael Levitan serves as the VP of Investor Relations and Corporate Communications, reachable at +1 (908) 705 1696 or via email.
Media Inquiries
For media relations, the team is ready to assist with any inquiries. Saskia Mehring is the Corporate Communications Manager and can be contacted at +31 6 28 32 60 41 or through the media email address. Pharming is poised and ready to share its stories and advancements on this global platform.
Frequently Asked Questions
What is the Oppenheimer Movers in Rare Disease Summit?
This summit is a focused event bringing together leaders in the rare diseases sector, including innovative companies and investors.
Who is representing Pharming at the summit?
Dr. Anurag Relan, the Chief Medical Officer, will represent Pharming in discussions regarding hereditary angioedema.
What type of therapies does Pharming develop?
Pharming develops innovative medications, including both small molecules and biologics, aimed at treating rare diseases.
How can investors meet Pharming's management?
Investors can schedule one-on-one meetings by contacting Pharming's Investor Relations team directly.
Where is Pharming Group headquartered?
Pharming is headquartered in Leiden, the Netherlands, with a notable workforce also based in the United States.
